Table 2.

53BP1 protein expression level and correlation with clinico-pathological parameters

		53BP1 protein expression level (Low < 9.6 U / mg Protein, High ≥9.6 pg/mg Protein)
Patients’ characteristics	N (%)	Low n (%)	High n (%)	p
Age at diagnosis (years)				1
Median (range)	54 (29–75)
≤ 54	80 (52.6%)	40 (52.6%)	40 (52.6%)
> 54	72 (47.4%)	36 (47.4%)	36 (47.5%)
Menopausal status				0.87
Pre-menopausal	69 (44.7%)	34 (44.7%)	35 (46.1%)
Post-menopausal	83 (55.3%)	42 (55.3%)	41 (53.9%)
T classification				0.57
T1	75 (49.3%)	37 (48.7%)	38 (50%)
T2	73 (48%)	38 (50%)	35 (46.1%)
T3-4	4 (2.6%)	1 (1.3%)	3 (3.9%)
N classification				0.015
N0	104 (68.4%)	59 (77.6%)	45 (59.2%)
N+	48 (31.6%)	17 (22.4%)	31 (40.8%)
Histology				0.44
Ductal	117 (77%)	58 (76.4%)	59 (77.6%)
Lobular	9 (5.9%)	3 (3.9%)	6 (7.9%)
Other	26 (17.1%)	15 (19.7%)	11 (14.5%)
Grade				0.46
I / II	1 (0.7%) / 50 (32.9%)	23 (30.3%)	28 (36.8%)
III	101 (66.4%)	53 (69.7%)	48 (63.2%)
ER				0.005
Positive	87 (57.2%)	35 (46.1%)	52 (68.4%)
Negative	65 (42.8%)	41 (53.9%)	24 (31.6%)
PR				0.013
Positive	59 (38.8%)	22 (28.9%)	37 (48.7%)
Negative	93 (61.2%)	54 (71.1%)	39 (51.3%)
HER2				0.73
Positive	48 (31.6%)	25 (32.9%)	23 (30.3%)
Negative	104 (68.4%)	51 (67.1%)	53 (69.7%)
Molecular profile grouping				0.022
HER2+	48 (31.6%)	25 (32.9%)	23 (30.3%)
HR+/HER2-	57 (37.5%)	21 (27.6%)	36 (47.4%)
Triple Negative	47 (30.9%)	30 (39.5%)	17 (22.4%)
BRCA1 methylation Status				0.045
Methylated	18 (11.8%)	13 (17.1%)	5 (6.6%)
Not Methylated	134 (88.2%)	63 (82.9%)	71 (93.4%)
PARP activity				0.048
≤ 2.6 U/mg Prot	39 (25.6%)	21 (27.6%)	18 (23.8%)
2.7 - 7	41 (27%)	27 (35.5%)	14 (18.4%)
7.1 - 14	36 (23.7%)	14 (18.4%)	22 (28.9%)
> 14	36 (23.7%)	14 (18.4%)	22 (28.9%)